Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival outcomes in isolated severe tricuspid regurgitation according to therapeutic modalities: a systematic review and meta-analysis.

Open heart·2025
Same author

Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2.

Journal of the American College of Cardiology·2024
Same author

Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.

The New England journal of medicine·2024
Same author

Sex-related differences in severe native valvular heart disease: the ESC-EORP Valvular Heart Disease II survey.

European heart journal·2024
Same author

Management of Massive Thrombosis of a Tendyne Valve: The Importance of Heart Valve Centers.

JACC. Case reports·2024
Same author

Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials.

European journal of heart failure·2024

Related Experiment Video

Updated: May 14, 2026

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

Transcatheter aortic valve replacement: current application and future directions.

Amir-Ali Fassa1, Dominique Himbert, Alec Vahanian

  • 1Cardiology Department, Hôpital Bichat, Paris, France.

Current Cardiology Reports
|February 20, 2013
PubMed
Summary

Transcatheter aortic valve replacement (TAVR) is a leading treatment for severe aortic stenosis, offering improved survival and symptom relief. Further research on prosthesis durability and complication reduction is needed as TAVR indications expand.

Related Experiment Videos

Last Updated: May 14, 2026

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Medical Devices

Background:

  • Severe aortic stenosis treatment has been revolutionized by transcatheter aortic valve replacement (TAVR).
  • TAVR is the standard for inoperable patients and an alternative for high-risk surgical candidates.
  • Multicenter registries confirm excellent hemodynamic performance and patient benefits.

Purpose of the Study:

  • To review the current status and future directions of transcatheter aortic valve replacement (TAVR).
  • To highlight the importance of a multidisciplinary heart team approach in TAVR procedures.
  • To identify areas for future research, including prosthesis durability and complication reduction.

Main Methods:

  • Review of large multicenter registries and clinical trials (e.g., PARTNER A and B).
  • Analysis of hemodynamic performance, symptom relief, and survival data for TAVR.
  • Discussion of current limitations and future indications for TAVR.

Main Results:

  • TAVR demonstrates excellent hemodynamic performance and improves survival and symptom relief.
  • The Edwards SAPIEN and Medtronic CoreValve are the primary percutaneous valves used.
  • A multidisciplinary heart team approach is crucial for optimal TAVR outcomes.

Conclusions:

  • TAVR is a well-established treatment for severe aortic stenosis, with expanding indications.
  • Further data on long-term prosthesis durability and complication rates are necessary.
  • Advancements in device miniaturization will likely increase the use of the transfemoral approach.